.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,521,423

« Back to Dashboard

Claims for Patent: 7,521,423

Title:Exendin pharmaceutical compositions
Abstract:Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Inventor(s): Young; Andrew A. (La Jolla, CA), Gedulin; Bronislava (Del Mar, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/896,244
Patent Claims: 1. A pharmaceutical composition comprising an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient; a pharmaceutically acceptable buffer; a pharmaceutically acceptable isotonicity agent; and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein the buffer is an acetate buffer.

3. The pharmaceutical composition of claim 1, wherein the isotonicity agent is mannitol, sorbitol, or a combination thereof.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is water, lactose, glucose, sucrose, starch, a cellulose derivative, a gelatin, an oil, a polyethylene glycol, a physiologically compatible solvent, or a combination of two or more thereof.

5. The pharmaceutical composition of claim 1, wherein the composition is formulated to provide a single or divided daily dose of the exendin-4 peptide in an amount from 0.001 mg based on the 70 kg patient to 1 mg based on the 70 kg patient.

6. The pharmaceutical composition of claim 5, wherein the composition is formulated to provide a single daily dose.

7. The pharmaceutical composition of claim 5, wherein the composition is formulated to provide a divided daily dose.

8. The pharmaceutical composition of claim 5, in an amount from 0.01 mg based on the 70 kg patient to 1 mg based on the 70 kg patient.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a subcutaneously injectable pharmaceutical composition.

10. A pharmaceutical composition comprising an exendin-4 peptide which comprises the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient; a pharmaceutically acceptable isotonicity agent selected from the group consisting of sodium chloride, dextrose, boric acid, sodium tartrate, propylene glycol, a polyol, and a combination of two or more thereof; and a pharmaceutically acceptable buffer.

11. The pharmaceutical composition of claim 10, wherein the composition is formulated to provide a single or divided daily dose of the exendin-4 peptide in an amount from 0.001 mg based on the 70 kg patient to 1 mg based on the 70 kg patient.

12. The pharmaceutical composition of claim 10, wherein the isotonicity agent is a polyol.

13. The pharmaceutical composition of claim 12, wherein the polyol is (i) mannitol, (ii) sorbitol, or a combination thereof.

14. The pharmaceutical composition of claim 10, wherein the buffer is an acetate buffer.

15. The pharmaceutical composition of claim 10, further comprising a pharmaceutically acceptable carrier selected from the group consisting of water, lactose, glucose, sucrose, starch, a cellulose derivative, gelatin, an oil, a polyethylene glycol, a physiologically compatible solvent, and a combination of two or more thereof.

16. The pharmaceutical composition of claim 10, wherein the composition is formulated for intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, or transmucosal administration.

17. The pharmaceutical composition of claim 10, wherein the exendin-4 peptide comprises an exendin-4 acid, an exendin-4 amide, or a combination thereof.

18. The pharmaceutical composition of claim 11, wherein the composition is formulated to provide a single daily dose.

19. The pharmaceutical composition of claim 11, wherein the composition is formulated to provide a divided daily dose.

20. The pharmaceutical composition of claim 11, in an amount from 0.01 mg based on the 70 kg patient to 1 mg based on the 70 kg patient.

21. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is a subcutaneously injectable pharmaceutical composition.

22. A pharmaceutical composition comprising (i) an exendin-4 peptide which comprises the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient; (ii) mannitol, sorbitol, or a combination thereof; and (iii) an acetate buffer.

23. The pharmaceutical composition of claim 22, wherein the exendin-4 peptide comprises an exendin-4 acid, an exendin-4 amide, or a combination thereof.

24. The pharmaceutical composition of claim 22, wherein the composition is formulated to provide a single or divided daily dose of the exendin-4 peptide in an amount from 0.001 mg based on the 70 kg patient to 1 mg based on the 70 kg patient.

25. The pharmaceutical composition of claim 24, wherein the composition is formulated to provide a single daily dose.

26. The pharmaceutical composition of claim 24, wherein the composition is formulated to provide a divided daily dose.

27. The pharmaceutical composition of claim 24, in an amount from 0.01 mg based on the 70 kg patient to 1 mg based on the 70 kg patient.

28. The pharmaceutical composition of claim 22, wherein the pharmaceutical composition is a subcutaneously injectable pharmaceutical composition.

29. A subcutaneously injectable pharmaceutical composition comprising (i) an exendin-4 peptide which comprises the amino acid sequence of SEQ ID NO. 2 in an amount from 0.001 mg based on a 70 kg patient to 1 mg based on a 70 kg patient; (ii) mannitol, sorbitol, or a combination thereof; (iii) an acetate buffer; and (iv) a pharmaceutically acceptable aqueous carrier.

30. The pharmaceutical composition of claim 29, wherein the composition is formulated to provide a single or divided daily dose of the exendin-4 peptide in an amount from 0.001 mg based on the 70 kg patient to 1 mg based on the 70 kg patient.

31. The pharmaceutical composition of claim 29, wherein the composition is formulated to provide a single daily dose.

32. The pharmaceutical composition of claim 29, wherein the composition is formulated to provide a divided daily dose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc